Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris LK, Griffiths CEM, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin CY, Papp K. Leonardi C, et al. Among authors: gerdes s. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21. Dermatol Ther (Heidelb). 2020. PMID: 32200512 Free PMC article.
Psoriasis: to treat or to manage?
Mrowietz U, Steinz K, Gerdes S. Mrowietz U, et al. Among authors: gerdes s. Exp Dermatol. 2014 Oct;23(10):705-9. doi: 10.1111/exd.12437. Epub 2014 Aug 2. Exp Dermatol. 2014. PMID: 24815425 Review.
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S. Gottlieb AB, et al. Among authors: gerdes s. J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27696577 Free PMC article.
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J; EGALITY study group; Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M. Griffiths CEM, et al. Among authors: gerdes s. Br J Dermatol. 2017 Apr;176(4):928-938. doi: 10.1111/bjd.15152. Epub 2017 Mar 1. Br J Dermatol. 2017. PMID: 27787890 Clinical Trial.
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H. Gerdes S, et al. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-427. doi: 10.1111/jdv.14605. Epub 2017 Nov 2. J Eur Acad Dermatol Venereol. 2018. PMID: 28960486 Free PMC article. Clinical Trial.
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Thaçi D, et al. Among authors: gerdes s. Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20. Br J Dermatol. 2020. PMID: 31705526 Clinical Trial.
Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Rissler M, Gathmann S, Sieder C, Baeumer D, Orsenigo R. Augustin M, et al. Among authors: gerdes s. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2548-2556. doi: 10.1111/jdv.16400. Epub 2020 May 20. J Eur Acad Dermatol Venereol. 2020. PMID: 32239541
A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
Wilsmann-Theis D, Kromer C, Gerdes S, Linker C, Magnolo N, Sabat R, Reich K, Mössner R. Wilsmann-Theis D, et al. Among authors: gerdes s. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):2045-2050. doi: 10.1111/jdv.17441. Epub 2021 Jun 24. J Eur Acad Dermatol Venereol. 2021. PMID: 34077577 Clinical Trial.
226 results